Top 100 medical and healthcare startups in UK
Nov 26, 2025
|
Like
16
1
Funding: $414M
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
2
Funding: $10M
Emm is developing the first smart menstrual cup with integrated biosensors, which provides data on reproductive and menstrual health. The device functions like a regular menstrual cup, designed to store menstrual blood. The built-in sensor collects data that helps users understand their cycle patterns. Tracking the amount of menstrual fluid you lose each day helps you identify your heaviest days, plan your day and manage your menstrual cycle. Personalized insights can be viewed in the smartphone app. Data collected in the Emm app is encrypted and stored securely with two-factor authentication. Personal identifiers are removed or replaced with codes.
Emm is developing the first smart menstrual cup with integrated biosensors, which provides data on reproductive and menstrual health. The device functions like a regular menstrual cup, designed to store menstrual blood. The built-in sensor collects data that helps users understand their cycle patterns. Tracking the amount of menstrual fluid you lose each day helps you identify your heaviest days, plan your day and manage your menstrual cycle. Personalized insights can be viewed in the smartphone app. Data collected in the Emm app is encrypted and stored securely with two-factor authentication. Personal identifiers are removed or replaced with codes.
3
Funding: £1.1B
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
4
Funding: $1.3B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
5
Funding: $1.2B
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
6
Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
7
Funding: $1.1B
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
8
Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
9
Funding: $601.7M
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
10
Funding: $474.4M
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
11
Funding: $430M
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
12
Funding: $421.2M
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
13
Funding: $411.7M
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
14
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
15
Funding: $383.3M
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
16
Funding: $322.6M
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
17
Funding: $322.6M
Huma offers a health platform used for remote patient monitoring and biological data gathering for preventative healthcare.
Huma offers a health platform used for remote patient monitoring and biological data gathering for preventative healthcare.
18
Funding: $302.1M
Freeline Therapeutics is a biopharmaceutical company specialising in developing liver directed gene therapies for bleeding disorders.
Freeline Therapeutics is a biopharmaceutical company specialising in developing liver directed gene therapies for bleeding disorders.
19
Funding: $292M
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
20
Funding: $290.1M
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
